US 12,419,864 B2
Method for treating cancers
Hung-Kun Hsu, New Taipei (TW)
Assigned to Acura Nanomedicine Corporation, New Taipei (TW)
Appl. No. 17/770,289
Filed by Acura Nanomedicine Corporation, New Taipei (TW)
PCT Filed Oct. 20, 2020, PCT No. PCT/CN2020/122269
§ 371(c)(1), (2) Date Apr. 20, 2022,
PCT Pub. No. WO2021/078126, PCT Pub. Date Apr. 29, 2021.
Claims priority of provisional application 62/923,631, filed on Oct. 21, 2019.
Claims priority of provisional application 62/923,629, filed on Oct. 21, 2019.
Prior Publication US 2022/0387391 A1, Dec. 8, 2022
Int. Cl. A61K 31/4168 (2006.01); A61K 31/4706 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4168 (2013.01) [A61K 31/4706 (2013.01); A61P 35/00 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method for treating a cancer resistant to an anti-cancer agent in a subject, comprising administering to the subject an effective amount of an anti-parasitic agent and an autophagy inhibitor, wherein,
the cancer is resistant to gemcitabine;
the anti-parasitic agent is mebendazole (MBZ); and
the autophagy inhibitor is chloroquine (CQ):
wherein the cancer is brain tumor, liver cancer, or pancreatic cancer.